Download MendeleyDiscovery of BAY 3389934 Hydrochloride: A Potent and Selective Small-Molecule Dual Factor IIa/Xa Inhibitor with Short Half-Life for the Acute Treatment of Sepsis-Induced Coagulopathy.
Beck, H., Mesch, S., Zimmermann, S., Vakalopoulos, A., Lehmann, L., Gericke, K.M., Sussmeier, F., Baerfacker, L., Hillisch, A., Meier, K., Tersteegen, A., Buchmuller, A., Gerdes, C., Dietze-Torres, J., Kersten, E., Partikel, K., Brohl, A., Levilain, G., Heitmeier, S., Pfaff, N., Follmann, M.(2025) J Med Chem 68: 12687-12707
- PubMed: 40498640 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00538
- Primary Citation Related Structures:
9R8Q, 9R8R - PubMed Abstract:
Sepsis-induced coagulopathy (SIC) is a severe and frequent complication of sepsis, which is associated with high mortality in patients. So far, attempts have failed to establish a global standard of care in this difficult-to-treat indication. Anticoagulation with a dual inhibitor of the coagulation factors IIa (FIIa, thrombin) and Xa (FXa) has the potential to improve the treatment of life-threatening acute coagulation disorders, such as SIC. Herein, we describe the discovery of BAY 3389934 hydrochloride ( 31 ), a potent and highly selective, direct dual FIIa/Xa inhibitor, with high solubility suited for i.v. application. This small molecule acts as a metabolically soft active pharmaceutical ingredient (API) due to a labile carboxylic ester group, which is responsible for the desired short pharmacokinetic and pharmacological half-life ( t 1/2 ), resulting in a high controllability of the pharmacological action.
- Bayer AG, Pharmaceuticals, Research & Development, 42113 Wuppertal, Germany.
Organizational Affiliation:
